

WARPNINE

Charging at warp speed to find the cancer treatments of the future!



More Australians die from pancreatic, gastro-intestinal and rare cancers each year than prostate and breast cancers combined.

Together, they are the most common cancers in Australia, directly affecting more than 28,600 Australians each year and claiming a devastating 39 lives each day.

from our Chair and Chief Executive Officer

Dear friends,

We are writing with the joyful news that we have established a charitable foundation dedicated to addressing the inequity in cancer outcomes for what are essentially underfunded and under-researched malignancies. Warpnine is a Western Australian first.

WARPNINE IS THE WA RESEARCH INTO PANCREATIC, GASTROINTESTINAL AND RARE CANCERS.



"The need for dedicated research, greater awareness and increased support for people and families impacted by these cancers, has never been so compelling."

- Meg Croucher, Warpnine CEO

The support that we have received to-date has been tremendous, and we are sincerely grateful to our founding donors and community supporters for their generosity. Research grants rarely fund clinical trials or experimental treatments, or the innovative new technologies and resources needed to undertake these projects. By donating to Warpnine, you will provide Western Australia's leading, and internationally recognised researchers, with the funding and specialised technologies they need to make vital new discoveries in the treatment of these cancers.

The end of financial year is an opportunity to feel the joy of giving. Whether you support a clinical trial, translational research, or new technology, you can be assured that your gift will make a difference. All donations are gratefully received and 100% tax-deductible, with the entire sum of your donation being allocated to Warpnine and the provision of our initiatives.

Together, we can charge at warp speed to find the cancer treatments of the future, and significantly improve survival rates and outcomes for these devastating and often fatal cancers.

Dr Andrew Dean, Chair, and Meg Croucher, CEO



Supporting a revolutionary clinical trial for aggressive pancreatic cancers

An exciting new clinical trial is on the horizon, giving hope to patients and families impacted by pancreatic cancer.

Thanks to our amazing ambassadors and donations from the community, Warpline has commenced its first donor supported clinical trial, the i-CEND trial.

Pancreatic cancer has the highest mortality rate among all main cancer types. It is the third leading cause of cancer death in Australia, with a one-year survival rate of less than 35% and grim five-year survival rate of 11.5%.

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy that accounts for more than 90% of pancreatic cancer cases. PDAC's are difficult to treat due to the dense capsule that surrounds the tumour, prohibiting anti-cancer drugs from penetrating the diseased tissue. CEND-1 is an investigational drug that homes to tumours, modifying the tumour microenvironment into a temporary drug conduit, allowing cancer fighting agents to penetrate the tumour, including we believe, immune cells and immunotherapy antibodies.

Currently, pancreatic cancer is regarded as immunotherapy resistant. We believe that we can change this by using CEND with immunotherapy and chemotherapy together, to engage the immune system to fight against the cancer.

If we can demonstrate the safety and efficacy of CEND-1, we may subsequently apply this rationale to numerous other cancers and associated treatment regimes, improving survival outcomes for patients in Western Australia and ultimately, worldwide.

For more information or to discuss how you can help to support revolutionary clinical trials here in Western Australia, please contact Meg Croucher on 0406 818 810 or meg@warpline.org.au

Together, we are charging at warp speed to find the cancer treatments of the future, today!

Why I Give...

Philanthropy often comes from a desire to pay-it-forward to enrich the lives of others and of future generations. The ability to give back to a cause that has had personal impact can be a powerful motivator.



We asked one of our wonderful donors, Mr Nick Draper, to share the story behind why he chooses to give.



Nick Draper, Paying it forward

In late 2018, at age 51, I was diagnosed with Stage 4 Melanoma. Melanoma is a dangerous form of skin cancer and those diagnosed with Stage 4 Melanoma have traditionally had a dismal five-year survival rate of 19.9%.

The mere fact that I am here today, and leading a virtually unchanged life, is due to Dr Andrew Dean and the early-stage investment and subsequent research into new treatments for the management and potential cure, of rare and aggressive cancers.



Dr Dean, who I hope you never have to meet in a professional capacity, is a passionate visionary with an incredible team that have made it their mission to address the inequities in cancer outcomes and improve survival rates for people faced with rare and difficult to diagnose and treat cancers. Immunotherapy, which has been my saviour; is a type of cancer treatment that boosts the body's natural defences to fight cancer. The full spectrum of applications for immunotherapy are still being explored, with its ultimate impact likened to the introduction of penicillin and antibiotics in the fight against infection back in the 1920's.

As a grateful recipient of Dr Dean's innovative and exploratory work, I believe that I am in a unique position to support the next generation by being able to motivate a "PAY it FORWARD" mentality.

Last year, with the support of my network, we raised funds that are now helping to support a clinical trial, projected to enable better outcomes for patients diagnosed with pancreatic cancer.

The treatments of the future will only be possible if we back people like Dr Dean, together, we can raise vital funds that support Warpline in their vision to significantly improve survival rates from pancreatic, gastro-intestinal and rare cancers, and give people like me hope.



Making a Difference



DONATE TODAY



Scan the QR Code to donate online today



Complete the form below and return to:
Suite C202, 12 Salvado Road Subiaco, WA 6008

Yes, I/we would like to support Warprine to find the cancer treatments of the future and improve patient outcomes.

Please accept my/our gift of: \$25 \$50 \$100 \$250 or \$_____

Monthly Donation I'd like to make this a regular gift to maximise my impact
All donations of \$2 and over are tax-deductible. Warprine Incorporated ABN 25 683 900 655

Name

Address

Email Address

Providing your email address allows us to email your tax receipt to you, minimising cost and environmental impact

Payment Details

Please debit the above amount to my credit card Mastercard Visa or My cheque is enclosed
(made payable to Warprine Incorporated)

<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------	----------------------

Card Holder's Name

Expiry Date

Signature

Date of Birth

Leaving a Legacy Gift

By leaving a gift in your Will to Warprine Incorporated, you can help us to find the cancer treatments of the future, today.

I am interested in leaving a legacy gift, please contact me at: _____

We respect your privacy. If you would prefer not to receive further communication from Warprine please contact us.